Given the pharmacogenetic importance of ABCB1 and ABCC2 variants, this study aimed to identify the mechanisms by which genetic variations may contribute to the induction of ADRs and impact survival in patients with NSCLC treated with carboplatin and paclitaxel. Here, ABCB1 is linked to non-small cell lung carcinoma.